Gastrointestinal Cancer

Latest News

Perioperative Chemo Provides Significant OS Benefit vs Neoadjuvant Chemoradiation in Esophageal Cancer
Perioperative Chemo Provides Significant OS Benefit vs Neoadjuvant Chemoradiation in Esophageal Cancer

June 2nd 2024

Perioperative chemotherapy with FLOT improved overall survival in patients with resectable esophageal cancer compared with neoadjuvant chemoradiation with CROSS.

Adjuvant Imatinib Maintenance for 6 Years Lowers Recurrence Risk in High-Risk GIST
Adjuvant Imatinib Maintenance for 6 Years Lowers Recurrence Risk in High-Risk GIST

May 29th 2024

Approval of Infigratinib Withdrawn by the FDA for Advanced FGFR2+ Cholangiocarcinoma
Approval of Infigratinib Withdrawn by the FDA for Advanced FGFR2+ Cholangiocarcinoma

May 20th 2024

BLA for Zenocutuzumab Gets Priority Review for NRG1+ NSCLC, Pancreatic Cancer
BLA for Zenocutuzumab Gets Priority Review for NRG1+ NSCLC, Pancreatic Cancer

May 19th 2024

Pembrolizumab Plus Trastuzumab/Chemo Significantly Improves OS in Gastric/GEJ Cancer
Pembrolizumab Plus Trastuzumab/Chemo Significantly Improves OS in Gastric/GEJ Cancer

May 16th 2024

Latest CME Events & Activities

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

The 14th Asia-Pacific Primary Liver Cancer Expert Meeting

July 18 - 20, 2024

Register Now!

Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

2024 International Symposium of Gastrointestinal Oncology (ISGIO)

October 11-12, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

More News

© 2024 MJH Life Sciences

All rights reserved.